Report initial proof-of-concept data for nula-cel
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Aug 2022
- Due
- 30 Jun 2023
- Checked
- 3 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The company now anticipates sharing initial proof-of-concept data in mid-2023.”
What we found
Evidence strength A What the grades mean
Company announced in January 2023 it would not meet its mid-2023 guidance for initial proof-of-concept data due to serious adverse event in trial.
-
A 424B3 SEC Filing
“In February 2023, the Company announced its decision to discontinue the development of nula-cel and initiate a process to explore strategic alternatives.” not found on the page
-
B Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study
“As a result, the company will not meet its guidance for initial proof-of-concept data in mid-2023.” ✓ confirmed on the page
Checked 3 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- initial proof-of-concept data for nula-cel
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you LENZ Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-LENZ-003351 · Corrections policy